SCHEMBL502831

SCHEMBL502831

C[C@H](C(=O)O)N(c1ccccc1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
CYP2D6 P10635 1/20 0.44
SRC P12931 1/20 0.44
LMNA P02545 4/20 0.44
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TP53 P04637 1/20 0.44
NPC1 O15118 1/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
KMT2A Q03164 1/20 0.44
MAPK1 P28482 1/20 0.43
ALOX5 P09917 1/20 0.42
GLA P06280 1/20 0.42
TSHR P16473 1/20 0.42
PGR P06401 1/20 0.41
ADRA2A P08913 1/20 0.41
ADRA2B P18089 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL93387 1.00 PTGS2 (0.45) PTGS2NPSR1CYP2D6SRCLMNA
SCHEMBL157605 1.00 PTGS2 (0.45) PTGS2NPSR1CYP2D6SRCLMNA
SCHEMBL28995220 0.98 PTGS2 (0.44) PTGS2NPSR1CYP2D6SRCLMNA
SCHEMBL27745764 0.90 TRPM8 (0.45) LMNAALDH1A1SMN1; SMN2NPC1MAPT
SCHEMBL6216112 0.86 RAB9A (0.44) ALDH1A1SMN1; SMN2TP53NPC1MAPT
SCHEMBL6216109 0.86 RAB9A (0.44) ALDH1A1SMN1; SMN2TP53NPC1MAPT
SCHEMBL14463144 0.82 NPSR1 (0.44) PTGS2NPSR1CYP2D6SRCLMNA
SCHEMBL27567147 0.82 ALDH1A1 (0.41) PTGS2NPSR1LMNAALDH1A1SMN1; SMN2
SCHEMBL3381199 0.81 ALOX5 (0.44) LMNAALDH1A1SMN1; SMN2KMT2AALOX5
SCHEMBL21382545 0.81 KMT2A (0.44) CYP2D6ALDH1A1NPC1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4582436-A2 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 BicycleTX Limited (GB) 2025-07-09 EP claimed
US-20240000957-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 BICYCLETX LIMITED (GB) 2024-01-04 US claimed
US-11696956-B2 Bicyclic peptide ligands specific for EphA2 BICYCLETX LIMITED (GB) 2023-07-11 US claimed
US-20220289794-A1 SYNTHETIC ANTIMICROBIAL PEPTIDES AJK BIOPHARMACEUTICAL LLC (US) 2022-09-15 US claimed
EP-4021476-A1 SYNTHETIC ANTIMICROBIAL PEPTIDES AJK Biopharmaceutical, LLC (US) 2022-07-06 EP claimed
EP-3208279-B1 MINI-HEPCIDIN PEPTIDES AND METHODS OF USING THEREOF UNIV CALIFORNIA (US) 2021-04-21 EP claimed
WO-2021042039-A1 SYNTHETIC ANTIMICROBIAL PEPTIDES AJK PHARMACEUTICAL LLC (US) 2021-03-04 WO claimed
EP-2748183-B1 POTENT LIGANDS OF THE GHRELIN RECEPTOR UNIV LEIPZIG (DE) 2018-12-26 EP claimed
US-9718861-B2 Potent ligands of the ghrelin receptor UNIVERSITAET LEIPZIG (DE) 2017-08-01 US claimed
EP-2373679-B1 MINI-HEPCIDIN PEPTIDES AND METHODS OF USING THEREOF UNIV CALIFORNIA (US) 2017-03-08 EP claimed
CN-106188224-A A kind of multiple target-point anti-cancer medicine and preparation method and application 广东工业大学 2016-12-07 CN claimed
US-20150274781-A1 POTENT LIGANDS OF THE GHRELIN RECEPTOR UNIVERSITAET LEIPZIG (DE) 2015-10-01 US claimed
EP-2748183-A1 POTENT LIGANDS OF THE GHRELIN RECEPTOR Universität Leipzig (DE) 2014-07-02 EP claimed
US-8435941-B2 Mini-hepcidin peptides and methods of using thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-05-07 US claimed
WO-2013026927-A1 POTENT LIGANDS OF THE GHRELIN RECEPTOR UNIVERSITÄT LEIPZIG (DE) 2013-02-28 WO claimed
EP-2562181-A1 Potent ligands of the ghrelin receptor Universität Leipzig (DE) 2013-02-27 EP claimed
EP-1932852-A1 Novel taxane related peptides and uses thereof Campiani, Giuseppe (IT) 2008-06-18 EP claimed
US-20260001924-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME NEW YORK UNIVERSITY (US) 2026-01-01 US disclosed
US-5939554-A Diarylaminopropanediol and diarylmethyl-oxazolidinone compounds NDSU RESEARCH FOUNDATION (US) 1999-08-17 US disclosed
US-5623087-A Method for preparation of optically active diarylalanines NDSU-RESEARCH FOUNDATION (US) 1997-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11696956-B2 Bicyclic peptide ligands specific for EphA2 EPHA2, EPHB2, ERBB2 PTGS2 2504/4885NPSR1 551/4885CYP2D6 3268/4885
US-20150274781-A1 POTENT LIGANDS OF THE GHRELIN RECEPTOR GIPR, GPR119, GRPR PTGS2 2281/4885NPSR1 64/4885CYP2D6 4578/4885
US-20220289794-A1 SYNTHETIC ANTIMICROBIAL PEPTIDES VIP, HM13, NGLY1 PTGS2 4551/4885NPSR1 1082/4885CYP2D6 4664/4885
US-20240000957-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 EPHA2, EPHB2, ERBB2 PTGS2 2504/4885NPSR1 551/4885CYP2D6 3268/4885
US-20260001924-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME DDX21, PHAX, RBX1 PTGS2 1345/4885NPSR1 2246/4885CYP2D6 4293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.